An Open-Label Comparison of the Efficacy and Safety of the Low-Molecular-Weight Heparin [certoparin sodium] (3000 U Anti-Xa Once Daily) With Unfractionated Heparin for the Prevention of Thromboembolic Complications in Acutely Ill Non-Surgical Patients.

Trial Profile

An Open-Label Comparison of the Efficacy and Safety of the Low-Molecular-Weight Heparin [certoparin sodium] (3000 U Anti-Xa Once Daily) With Unfractionated Heparin for the Prevention of Thromboembolic Complications in Acutely Ill Non-Surgical Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Certoparin sodium; Heparin
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Therapeutic Use
  • Acronyms CERTAIN
  • Sponsors Novartis
  • Most Recent Events

    • 01 Dec 2010 Results published in the Expert Opinion on Pharmacotherapy.
    • 11 Jul 2009 Results presented at the 22nd Congress of the International Society on Thrombosis and Haemostasis.
    • 03 Nov 2008 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top